149 related articles for article (PubMed ID: 36749089)
21. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
22. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment.
Obermajer N; Muthuswamy R; Odunsi K; Edwards RP; Kalinski P
Cancer Res; 2011 Dec; 71(24):7463-70. PubMed ID: 22025564
[TBL] [Abstract][Full Text] [Related]
23. In the ovine pituitary, CXCR4 is localized in gonadotropes and somatotropes and increases with elevated serum progesterone.
Sanchez NS; Quinn KE; Ashley AK; Ashley RL
Domest Anim Endocrinol; 2018 Jan; 62():88-97. PubMed ID: 29157995
[TBL] [Abstract][Full Text] [Related]
24. Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer Patients.
Dąbrowska E; Przylipiak A; Zajkowska M; Piskor BM; Sidorkiewicz I; Szmitkowski M; Lawicki S
Anticancer Res; 2020 Jun; 40(6):3221-3229. PubMed ID: 32487616
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of chemokine (C-X-C motif) receptor four (CXCR4) at the fetal-maternal interface during early gestation in sheep: alterations in expression of chemokines, angiogenic factors and their receptors.
Quinn KE; Prosser SZ; Kane KK; Ashley RL
J Anim Sci; 2017 Mar; 95(3):1144-11153. PubMed ID: 28380526
[TBL] [Abstract][Full Text] [Related]
26. CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.
Chen N; Jiang X; Wang J; Wu T; Cheng B; Xia J
Tumour Biol; 2016 Jan; 37(1):567-75. PubMed ID: 26232325
[TBL] [Abstract][Full Text] [Related]
27. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
28. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
29. Epithelial chemokine CXCL14 synergizes with CXCL12
Collins PJ; McCully ML; Martínez-Muñoz L; Santiago C; Wheeldon J; Caucheteux S; Thelen S; Cecchinato V; Laufer JM; Purvanov V; Monneau YR; Lortat-Jacob H; Legler DF; Uguccioni M; Thelen M; Piguet V; Mellado M; Moser B
FASEB J; 2017 Jul; 31(7):3084-3097. PubMed ID: 28360196
[TBL] [Abstract][Full Text] [Related]
30. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
31. The role of chemokine receptor CXCR4 in lung cancer.
Gangadhar T; Nandi S; Salgia R
Cancer Biol Ther; 2010 Mar; 9(6):409-16. PubMed ID: 20147779
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor beta and CXCR4/CXCL12 expression: differences by sex and hormonal status in lung adenocarcinoma.
Rodriguez-Lara V; Peña-Mirabal E; Baez-Saldaña R; Esparza-Silva AL; García-Zepeda E; Cerbon Cervantes MA; Diaz D; Fortoul TI
Arch Med Res; 2014 Feb; 45(2):158-69. PubMed ID: 24486245
[TBL] [Abstract][Full Text] [Related]
33. Differential activity and selectivity of N-terminal modified CXCL12 chemokines at the CXCR4 and ACKR3 receptors.
Jaracz-Ros A; Bernadat G; Cutolo P; Gallego C; Gustavsson M; Cecon E; Baleux F; Kufareva I; Handel TM; Bachelerie F; Levoye A
J Leukoc Biol; 2020 Jun; 107(6):1123-1135. PubMed ID: 32374043
[TBL] [Abstract][Full Text] [Related]
34. Role of CXCL12 and CXCR4 in normal cerebellar development and medulloblastoma.
Ozawa PM; Ariza CB; Ishibashi CM; Fujita TC; Banin-Hirata BK; Oda JM; Watanabe MA
Int J Cancer; 2016 Jan; 138(1):10-3. PubMed ID: 25400097
[TBL] [Abstract][Full Text] [Related]
35. CXCL12 (SDF-1)/CXCR4 pathway in cancer.
Teicher BA; Fricker SP
Clin Cancer Res; 2010 Jun; 16(11):2927-31. PubMed ID: 20484021
[TBL] [Abstract][Full Text] [Related]
36. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
37. Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia.
Butrym A; Gebura K; Iwaszko M; Kuliczkowski K; Bogunia-Kubik K; Mazur G
HLA; 2016 Jun; 87(6):432-8. PubMed ID: 27173875
[TBL] [Abstract][Full Text] [Related]
38. [Mechanism of EGFR Over-expression and Mutations Leading to
Biological Characteristics Changes of Human Lung Adenocarcinoma Cells
through CXCR4/CXCL12 Signaling Pathway].
Feng J; Wei X; Li C; Guo M; Peng M; Song Q; Han G
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):503-512. PubMed ID: 30037369
[TBL] [Abstract][Full Text] [Related]
39. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma: A potent biomarker predicting lymph node metastasis.
Dayer R; Babashah S; Jamshidi S; Sadeghizadeh M
J Cancer Res Ther; 2018; 14(2):345-350. PubMed ID: 29516917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
